Structural adaptation to ischemia in skeletal muscle: effects of blockers of the renin-angiotensin system

OBJECTIVETo investigate the effects of long-term treatment with blockers of the renin–angiotensin system on capillarization and growth of fibers in ischemic hind-limb muscles and in muscles under normal growth conditions. METHODSIschemia was induced by partial ligation of the left common iliac arter...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of hypertension 1997-12, Vol.15 (12), p.1455-1461
Hauptverfasser: Scheidegger, Kathrin J, Nelissen-Vrancken, Marjorie H.J.G, Leenders, Peter J.A, Daemen, Mat J.A.P, Smits, Jos F.M, Wood, Jeanette M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1461
container_issue 12
container_start_page 1455
container_title Journal of hypertension
container_volume 15
creator Scheidegger, Kathrin J
Nelissen-Vrancken, Marjorie H.J.G
Leenders, Peter J.A
Daemen, Mat J.A.P
Smits, Jos F.M
Wood, Jeanette M
description OBJECTIVETo investigate the effects of long-term treatment with blockers of the renin–angiotensin system on capillarization and growth of fibers in ischemic hind-limb muscles and in muscles under normal growth conditions. METHODSIschemia was induced by partial ligation of the left common iliac artery. RESULTSIschemia resulted in a significant increase in capillary and fiber density in the soleus muscle, a significant decrease in mean fiber size and a decrease in muscle cross-sectional area after 4 weeks compared with the contralateral nonischemic muscle. Ischemia also significantly decreased the muscle body weight ratio of the left soleus muscle. We observed no significant effect on total number of capillaries and capillaryfiber ratio, suggesting that ischemia did not result in an increase in capillarization in this muscle. Treatments with subhypotensive and with hypotensive doses of the angiotensin converting enzyme (ACE) inhibitor benazeprilat, the angiotensin (Ang) II AT1 antagonist valsartan, or the Ang II AT antagonist PD 123 319 for 4 weeks did not influence any of the above-described changes in the normal and ischemic muscles and treatment effects were also independent of the degree of reduction of blood pressure. CONCLUSIONTreatments with an ACE inhibitor and with Ang II receptor antagonists in dose ranges that moderately lower blood pressure do not influence vessel density and any of the other structural adaptations after hind-limb ischemia. Administrations of ACE inhibitors and Ang II AT1 antagonists may therefore be adequate and beneficial therapies under ischemic conditions, such as in the treatment of hypertension complicated by intermittent claudication, for which treatment must not increase ischemia.
doi_str_mv 10.1097/00004872-199715120-00013
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79512929</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79512929</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3293-faf6718f7bd8c431d80efc4ea3254a8fabbe37d9e9b53cc36010bcb6e10d260f3</originalsourceid><addsrcrecordid>eNp1kU1v3CAQhlGVKt1s-xMicahyc8KHbaC3KkrbSJFyaHtGGA9dsthsASvKvy-b3e4tXAbNvO8MPIMQpuSaEiVuSD2tFKyhSgnaUUaamqH8HVrRVvCm65Q8QyvCet70vGMf0EXOT1UileDn6Fy1nMqOrZD_WdJiy5JMwGY0u2KKjzMuEftsNzB5g_2M8xYClCqZlmwDfMHgHNiScXR4CNFuIb3eywZwgtnPjZn_-Fhgznv3Sy4wfUTvnQkZPh3jGv3-dvfr9kfz8Pj9_vbrQ2M5U7xxxvWCSieGUdr6ylEScLYFw1nXGunMMAAXowI1dNxa3hNKBjv0QMnIeuL4Gl0d-u5S_LtALnqqX4EQzAxxyVqoikvVUWskD0KbYs4JnN4lP5n0oinRe8r6P2V9oqxfKVfr5XHGMkwwnoxHrLX--Vg32ZrgkpmtzycZI5JSuW_THmTPMZSKcBuWZ0h6AyaUjX5rx_wfgoKWdA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79512929</pqid></control><display><type>article</type><title>Structural adaptation to ischemia in skeletal muscle: effects of blockers of the renin-angiotensin system</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Scheidegger, Kathrin J ; Nelissen-Vrancken, Marjorie H.J.G ; Leenders, Peter J.A ; Daemen, Mat J.A.P ; Smits, Jos F.M ; Wood, Jeanette M</creator><creatorcontrib>Scheidegger, Kathrin J ; Nelissen-Vrancken, Marjorie H.J.G ; Leenders, Peter J.A ; Daemen, Mat J.A.P ; Smits, Jos F.M ; Wood, Jeanette M</creatorcontrib><description>OBJECTIVETo investigate the effects of long-term treatment with blockers of the renin–angiotensin system on capillarization and growth of fibers in ischemic hind-limb muscles and in muscles under normal growth conditions. METHODSIschemia was induced by partial ligation of the left common iliac artery. RESULTSIschemia resulted in a significant increase in capillary and fiber density in the soleus muscle, a significant decrease in mean fiber size and a decrease in muscle cross-sectional area after 4 weeks compared with the contralateral nonischemic muscle. Ischemia also significantly decreased the muscle body weight ratio of the left soleus muscle. We observed no significant effect on total number of capillaries and capillaryfiber ratio, suggesting that ischemia did not result in an increase in capillarization in this muscle. Treatments with subhypotensive and with hypotensive doses of the angiotensin converting enzyme (ACE) inhibitor benazeprilat, the angiotensin (Ang) II AT1 antagonist valsartan, or the Ang II AT antagonist PD 123 319 for 4 weeks did not influence any of the above-described changes in the normal and ischemic muscles and treatment effects were also independent of the degree of reduction of blood pressure. CONCLUSIONTreatments with an ACE inhibitor and with Ang II receptor antagonists in dose ranges that moderately lower blood pressure do not influence vessel density and any of the other structural adaptations after hind-limb ischemia. Administrations of ACE inhibitors and Ang II AT1 antagonists may therefore be adequate and beneficial therapies under ischemic conditions, such as in the treatment of hypertension complicated by intermittent claudication, for which treatment must not increase ischemia.</description><identifier>ISSN: 0263-6352</identifier><identifier>EISSN: 1473-5598</identifier><identifier>DOI: 10.1097/00004872-199715120-00013</identifier><identifier>PMID: 9431852</identifier><identifier>CODEN: JOHYD3</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott-Raven Publishers</publisher><subject>Adaptation, Physiological - physiology ; Angiotensin Receptor Antagonists ; Angiotensin-Converting Enzyme Inhibitors - blood ; Angiotensin-Converting Enzyme Inhibitors - pharmacology ; Animals ; Benzazepines - pharmacology ; Biological and medical sciences ; Blood Pressure - drug effects ; Cardiovascular system ; Heart Rate - drug effects ; Hindlimb ; Imidazoles - pharmacology ; Ischemia - blood ; Ischemia - pathology ; Ischemia - physiopathology ; Male ; Medical sciences ; Muscle, Skeletal - blood supply ; Muscle, Skeletal - drug effects ; Muscle, Skeletal - pathology ; Muscles - blood supply ; Pharmacology. Drug treatments ; Pyridines - pharmacology ; Rats ; Rats, Inbred SHR ; Renin - blood ; Renin-Angiotensin System - drug effects ; Skin ; Space life sciences ; Tetrazoles - pharmacology ; Valine - analogs &amp; derivatives ; Valine - pharmacology ; Valsartan ; Vasodilator agents. Cerebral vasodilators</subject><ispartof>Journal of hypertension, 1997-12, Vol.15 (12), p.1455-1461</ispartof><rights>Lippincott-Raven Publishers.</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3293-faf6718f7bd8c431d80efc4ea3254a8fabbe37d9e9b53cc36010bcb6e10d260f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23929,23930,25139,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2081183$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9431852$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Scheidegger, Kathrin J</creatorcontrib><creatorcontrib>Nelissen-Vrancken, Marjorie H.J.G</creatorcontrib><creatorcontrib>Leenders, Peter J.A</creatorcontrib><creatorcontrib>Daemen, Mat J.A.P</creatorcontrib><creatorcontrib>Smits, Jos F.M</creatorcontrib><creatorcontrib>Wood, Jeanette M</creatorcontrib><title>Structural adaptation to ischemia in skeletal muscle: effects of blockers of the renin-angiotensin system</title><title>Journal of hypertension</title><addtitle>J Hypertens</addtitle><description>OBJECTIVETo investigate the effects of long-term treatment with blockers of the renin–angiotensin system on capillarization and growth of fibers in ischemic hind-limb muscles and in muscles under normal growth conditions. METHODSIschemia was induced by partial ligation of the left common iliac artery. RESULTSIschemia resulted in a significant increase in capillary and fiber density in the soleus muscle, a significant decrease in mean fiber size and a decrease in muscle cross-sectional area after 4 weeks compared with the contralateral nonischemic muscle. Ischemia also significantly decreased the muscle body weight ratio of the left soleus muscle. We observed no significant effect on total number of capillaries and capillaryfiber ratio, suggesting that ischemia did not result in an increase in capillarization in this muscle. Treatments with subhypotensive and with hypotensive doses of the angiotensin converting enzyme (ACE) inhibitor benazeprilat, the angiotensin (Ang) II AT1 antagonist valsartan, or the Ang II AT antagonist PD 123 319 for 4 weeks did not influence any of the above-described changes in the normal and ischemic muscles and treatment effects were also independent of the degree of reduction of blood pressure. CONCLUSIONTreatments with an ACE inhibitor and with Ang II receptor antagonists in dose ranges that moderately lower blood pressure do not influence vessel density and any of the other structural adaptations after hind-limb ischemia. Administrations of ACE inhibitors and Ang II AT1 antagonists may therefore be adequate and beneficial therapies under ischemic conditions, such as in the treatment of hypertension complicated by intermittent claudication, for which treatment must not increase ischemia.</description><subject>Adaptation, Physiological - physiology</subject><subject>Angiotensin Receptor Antagonists</subject><subject>Angiotensin-Converting Enzyme Inhibitors - blood</subject><subject>Angiotensin-Converting Enzyme Inhibitors - pharmacology</subject><subject>Animals</subject><subject>Benzazepines - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Cardiovascular system</subject><subject>Heart Rate - drug effects</subject><subject>Hindlimb</subject><subject>Imidazoles - pharmacology</subject><subject>Ischemia - blood</subject><subject>Ischemia - pathology</subject><subject>Ischemia - physiopathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Muscle, Skeletal - blood supply</subject><subject>Muscle, Skeletal - drug effects</subject><subject>Muscle, Skeletal - pathology</subject><subject>Muscles - blood supply</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyridines - pharmacology</subject><subject>Rats</subject><subject>Rats, Inbred SHR</subject><subject>Renin - blood</subject><subject>Renin-Angiotensin System - drug effects</subject><subject>Skin</subject><subject>Space life sciences</subject><subject>Tetrazoles - pharmacology</subject><subject>Valine - analogs &amp; derivatives</subject><subject>Valine - pharmacology</subject><subject>Valsartan</subject><subject>Vasodilator agents. Cerebral vasodilators</subject><issn>0263-6352</issn><issn>1473-5598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1v3CAQhlGVKt1s-xMicahyc8KHbaC3KkrbSJFyaHtGGA9dsthsASvKvy-b3e4tXAbNvO8MPIMQpuSaEiVuSD2tFKyhSgnaUUaamqH8HVrRVvCm65Q8QyvCet70vGMf0EXOT1UileDn6Fy1nMqOrZD_WdJiy5JMwGY0u2KKjzMuEftsNzB5g_2M8xYClCqZlmwDfMHgHNiScXR4CNFuIb3eywZwgtnPjZn_-Fhgznv3Sy4wfUTvnQkZPh3jGv3-dvfr9kfz8Pj9_vbrQ2M5U7xxxvWCSieGUdr6ylEScLYFw1nXGunMMAAXowI1dNxa3hNKBjv0QMnIeuL4Gl0d-u5S_LtALnqqX4EQzAxxyVqoikvVUWskD0KbYs4JnN4lP5n0oinRe8r6P2V9oqxfKVfr5XHGMkwwnoxHrLX--Vg32ZrgkpmtzycZI5JSuW_THmTPMZSKcBuWZ0h6AyaUjX5rx_wfgoKWdA</recordid><startdate>199712</startdate><enddate>199712</enddate><creator>Scheidegger, Kathrin J</creator><creator>Nelissen-Vrancken, Marjorie H.J.G</creator><creator>Leenders, Peter J.A</creator><creator>Daemen, Mat J.A.P</creator><creator>Smits, Jos F.M</creator><creator>Wood, Jeanette M</creator><general>Lippincott-Raven Publishers</general><general>Lippincott Williams &amp; Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199712</creationdate><title>Structural adaptation to ischemia in skeletal muscle: effects of blockers of the renin-angiotensin system</title><author>Scheidegger, Kathrin J ; Nelissen-Vrancken, Marjorie H.J.G ; Leenders, Peter J.A ; Daemen, Mat J.A.P ; Smits, Jos F.M ; Wood, Jeanette M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3293-faf6718f7bd8c431d80efc4ea3254a8fabbe37d9e9b53cc36010bcb6e10d260f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adaptation, Physiological - physiology</topic><topic>Angiotensin Receptor Antagonists</topic><topic>Angiotensin-Converting Enzyme Inhibitors - blood</topic><topic>Angiotensin-Converting Enzyme Inhibitors - pharmacology</topic><topic>Animals</topic><topic>Benzazepines - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Cardiovascular system</topic><topic>Heart Rate - drug effects</topic><topic>Hindlimb</topic><topic>Imidazoles - pharmacology</topic><topic>Ischemia - blood</topic><topic>Ischemia - pathology</topic><topic>Ischemia - physiopathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Muscle, Skeletal - blood supply</topic><topic>Muscle, Skeletal - drug effects</topic><topic>Muscle, Skeletal - pathology</topic><topic>Muscles - blood supply</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyridines - pharmacology</topic><topic>Rats</topic><topic>Rats, Inbred SHR</topic><topic>Renin - blood</topic><topic>Renin-Angiotensin System - drug effects</topic><topic>Skin</topic><topic>Space life sciences</topic><topic>Tetrazoles - pharmacology</topic><topic>Valine - analogs &amp; derivatives</topic><topic>Valine - pharmacology</topic><topic>Valsartan</topic><topic>Vasodilator agents. Cerebral vasodilators</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Scheidegger, Kathrin J</creatorcontrib><creatorcontrib>Nelissen-Vrancken, Marjorie H.J.G</creatorcontrib><creatorcontrib>Leenders, Peter J.A</creatorcontrib><creatorcontrib>Daemen, Mat J.A.P</creatorcontrib><creatorcontrib>Smits, Jos F.M</creatorcontrib><creatorcontrib>Wood, Jeanette M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Scheidegger, Kathrin J</au><au>Nelissen-Vrancken, Marjorie H.J.G</au><au>Leenders, Peter J.A</au><au>Daemen, Mat J.A.P</au><au>Smits, Jos F.M</au><au>Wood, Jeanette M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Structural adaptation to ischemia in skeletal muscle: effects of blockers of the renin-angiotensin system</atitle><jtitle>Journal of hypertension</jtitle><addtitle>J Hypertens</addtitle><date>1997-12</date><risdate>1997</risdate><volume>15</volume><issue>12</issue><spage>1455</spage><epage>1461</epage><pages>1455-1461</pages><issn>0263-6352</issn><eissn>1473-5598</eissn><coden>JOHYD3</coden><abstract>OBJECTIVETo investigate the effects of long-term treatment with blockers of the renin–angiotensin system on capillarization and growth of fibers in ischemic hind-limb muscles and in muscles under normal growth conditions. METHODSIschemia was induced by partial ligation of the left common iliac artery. RESULTSIschemia resulted in a significant increase in capillary and fiber density in the soleus muscle, a significant decrease in mean fiber size and a decrease in muscle cross-sectional area after 4 weeks compared with the contralateral nonischemic muscle. Ischemia also significantly decreased the muscle body weight ratio of the left soleus muscle. We observed no significant effect on total number of capillaries and capillaryfiber ratio, suggesting that ischemia did not result in an increase in capillarization in this muscle. Treatments with subhypotensive and with hypotensive doses of the angiotensin converting enzyme (ACE) inhibitor benazeprilat, the angiotensin (Ang) II AT1 antagonist valsartan, or the Ang II AT antagonist PD 123 319 for 4 weeks did not influence any of the above-described changes in the normal and ischemic muscles and treatment effects were also independent of the degree of reduction of blood pressure. CONCLUSIONTreatments with an ACE inhibitor and with Ang II receptor antagonists in dose ranges that moderately lower blood pressure do not influence vessel density and any of the other structural adaptations after hind-limb ischemia. Administrations of ACE inhibitors and Ang II AT1 antagonists may therefore be adequate and beneficial therapies under ischemic conditions, such as in the treatment of hypertension complicated by intermittent claudication, for which treatment must not increase ischemia.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott-Raven Publishers</pub><pmid>9431852</pmid><doi>10.1097/00004872-199715120-00013</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0263-6352
ispartof Journal of hypertension, 1997-12, Vol.15 (12), p.1455-1461
issn 0263-6352
1473-5598
language eng
recordid cdi_proquest_miscellaneous_79512929
source MEDLINE; Journals@Ovid Complete
subjects Adaptation, Physiological - physiology
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors - blood
Angiotensin-Converting Enzyme Inhibitors - pharmacology
Animals
Benzazepines - pharmacology
Biological and medical sciences
Blood Pressure - drug effects
Cardiovascular system
Heart Rate - drug effects
Hindlimb
Imidazoles - pharmacology
Ischemia - blood
Ischemia - pathology
Ischemia - physiopathology
Male
Medical sciences
Muscle, Skeletal - blood supply
Muscle, Skeletal - drug effects
Muscle, Skeletal - pathology
Muscles - blood supply
Pharmacology. Drug treatments
Pyridines - pharmacology
Rats
Rats, Inbred SHR
Renin - blood
Renin-Angiotensin System - drug effects
Skin
Space life sciences
Tetrazoles - pharmacology
Valine - analogs & derivatives
Valine - pharmacology
Valsartan
Vasodilator agents. Cerebral vasodilators
title Structural adaptation to ischemia in skeletal muscle: effects of blockers of the renin-angiotensin system
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T12%3A18%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Structural%20adaptation%20to%20ischemia%20in%20skeletal%20muscle:%20effects%20of%20blockers%20of%20the%20renin-angiotensin%20system&rft.jtitle=Journal%20of%20hypertension&rft.au=Scheidegger,%20Kathrin%20J&rft.date=1997-12&rft.volume=15&rft.issue=12&rft.spage=1455&rft.epage=1461&rft.pages=1455-1461&rft.issn=0263-6352&rft.eissn=1473-5598&rft.coden=JOHYD3&rft_id=info:doi/10.1097/00004872-199715120-00013&rft_dat=%3Cproquest_cross%3E79512929%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79512929&rft_id=info:pmid/9431852&rfr_iscdi=true